LU92854I2 - Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil - Google Patents

Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil Download PDF

Info

Publication number: LU92854I2
Authority: LU; Luxembourg
Prior art keywords: rilpivirine; tenofovir; protected; pharmaceutically acceptable; combination
Prior art date: 2003-09-03

Application number

LU92854C

Other languages

English (en)

Original Assignee

Janssen Sciences Ireland Uc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-03

Filing date

2015-10-21

Publication date

2015-12-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92854(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-10-21 Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc

2015-12-21 Publication of LU92854I2 publication Critical patent/LU92854I2/fr

Links

229960002814 rilpivirine Drugs 0.000 title 2
YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 title 2
KZVVGZKAVZUACK-BJILWQEISA-N rilpivirine hydrochloride Chemical class Cl.CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 KZVVGZKAVZUACK-BJILWQEISA-N 0.000 title 1
150000003839 salts Chemical class 0.000 title 1
229960004556 tenofovir Drugs 0.000 title 1
SGOIRFVFHAKUTI-ZCFIWIBFSA-N tenofovir (anhydrous) Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 title 1
229960004693 tenofovir disoproxil fumarate Drugs 0.000 title 1
VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

LU92854C 2003-09-03 2015-10-21 Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil LU92854I2 (fr)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
US49977103P	2003-09-03	2003-09-03
EP03103275		2003-09-03
EP03103319		2003-09-08
EP03103335		2003-09-10
EP03103668		2003-10-02
US50848603P	2003-10-03	2003-10-03
EP04787096.9A EP1663240B2 (fr)	2003-09-03	2004-09-03	Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
PCT/EP2004/052028 WO2005021001A1 (fr)	2003-09-03	2004-09-03	Combinaisons d'une pyrimidine renfermant nnrti avec des inhibiteurs de rt

Publications (1)

Publication Number	Publication Date
LU92854I2 true LU92854I2 (fr)	2015-12-21

Family

ID=34280181

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
LU92853C LU92853I2 (fr)	2003-09-03	2015-10-20	Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine
LU92855C LU92855I2 (fr)	2003-09-03	2015-10-21	Combinaison de rilpivirine ou une forme thérapeutique equivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, ténofovir, en particulier le fumarate de ténofovir disoproxil, et l'emtricitabine
LU92854C LU92854I2 (fr)	2003-09-03	2015-10-21	Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
LU92853C LU92853I2 (fr)	2003-09-03	2015-10-20	Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine
LU92855C LU92855I2 (fr)	2003-09-03	2015-10-21	Combinaison de rilpivirine ou une forme thérapeutique equivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, ténofovir, en particulier le fumarate de ténofovir disoproxil, et l'emtricitabine

Country Status (24)

Country	Link
US (9)	US20080200435A1 (fr)
EP (1)	EP1663240B2 (fr)
JP (3)	JP5507791B2 (fr)
KR (1)	KR20060090658A (fr)
CN (1)	CN101060844B (fr)
AP (1)	AP2109A (fr)
AU (5)	AU2004268390B2 (fr)
BE (1)	BE2015C053I2 (fr)
CA (1)	CA2537095C (fr)
CY (5)	CY2015038I1 (fr)
FI (1)	FI1663240T4 (fr)
FR (5)	FR15C0073I2 (fr)
HR (1)	HRP20150798T4 (fr)
HU (5)	HUS1500054I1 (fr)
IL (2)	IL173438A (fr)
LT (2)	LTPA2016045I1 (fr)
LU (3)	LU92853I2 (fr)
MX (1)	MXPA06002437A (fr)
MY (1)	MY169670A (fr)
NL (2)	NL300781I2 (fr)
NO (6)	NO334877B1 (fr)
NZ (1)	NZ545306A (fr)
PL (1)	PL1663240T5 (fr)
WO (1)	WO2005021001A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en)	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en)	2001-08-13	2012-01-24	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
PL208533B1 (pl)	2002-08-09	2011-05-31	Janssen Pharmaceutica Nv	Sposób otrzymywania 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu oraz sposób otrzymywania związku pośredniego
SI1583542T1 (sl)	2003-01-14	2008-12-31	Gilead Sciences Inc	Sestavki in postopki za kombinacijsko antivirusnoterapijo
PT1632232E (pt) *	2004-09-02	2011-08-02	Janssen Pharmaceutica Nv	Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
WO2006024668A1 (fr) *	2004-09-02	2006-03-09	Janssen Pharmaceutica N.V.	Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile
UA92469C2 (en) *	2004-09-02	2010-11-10	Янссен Фармацевтика Н.В.	Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
EP1789139B1 (fr) *	2004-09-02	2012-03-21	Janssen Pharmaceutica NV	Hydrochloride de 4-((4-((4-(2-cyanoéthényl)-2,6-diméthylphényl amino -2-pyrimidinyl amino benzonitrile
SI1789139T1 (sl) *	2004-09-02	2012-08-31	Janssen Pharmaceutica Nv	Fumarat 4-((4-((4-(2-cianoetenil)-2,6-dimetifenil amino-2-pirimidinil amino benzonitrila
TWI457136B (zh) *	2005-04-04	2014-10-21	Tibotec Pharm Ltd	Ｈｉｖ-感染之預防
TWI471145B (zh) *	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
TWI375560B (en) *	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
US20080317852A1 (en) *	2005-12-14	2008-12-25	Amar Lulla	Pharmaceutical Combination
RS52821B2 (sr) *	2006-01-20	2021-07-30	Janssen Sciences Ireland Unlimited Co	Dugotrajno tretiranje hiv-infekcije sa tcm278
US9044509B2 (en)	2006-02-03	2015-06-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (fr)	2006-07-05	2008-09-26	Univ Aix Marseille Ii	Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
TWI494133B (zh)	2007-03-14	2015-08-01	Tibotec Pharm Ltd	重組用粉末
CN101990432B (zh) *	2008-01-03	2016-01-20	艾克斯-马赛大学	抗hiv治疗期间使用的组合物和方法
NZ593950A (en) *	2008-12-24	2013-08-30	Janssen R & D Ireland	Implantable devices for treating hiv
RU2593790C2 (ru)	2009-12-21	2016-08-10	Янссен Сайенсиз Айрлэнд Юси	Разлагаемый удаляемый имплантат для непрерывного высвобождения активного соединения
RS54123B1 (sr)	2010-01-27	2015-12-31	Viiv Healthcare Company	Terapeutska kombinacija koja sadrži dolutegravir, abacavir i lamivudine
NZ610729A (en) *	2010-11-19	2015-10-30	Gilead Sciences Inc	Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
WO2012125993A1 (fr)	2011-03-17	2012-09-20	Teva Pharmaceutical Industries Ltd.	Formes à l'état solide de base rilpivirine et sels de rilpivirine
EP2755959B1 (fr) *	2011-09-16	2018-05-16	Hetero Research Foundation	Chlorhydrate de rilpivirine
SI2822954T1 (sl)	2012-12-21	2016-07-29	Gilead Sciences, Inc.	Policiklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
PE20181207A1 (es)	2015-11-09	2018-07-23	Gilead Sciences Inc	Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
HUE064823T2 (hu)	2016-10-24	2024-04-28	Janssen Sciences Ireland Unlimited Co	Diszpergálható készítmények
US20210128554A1 (en) *	2016-12-23	2021-05-06	Temple University - Of The Commonwealth System Of Higher Education	Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
JP2020517633A (ja) *	2017-04-18	2020-06-18	シプラ・リミテッド	レトロウイルス感染の治療に用いる併用療法
WO2019021319A1 (fr) *	2017-07-27	2019-01-31	Cipla Limited	Compositions pharmaceutiques
CA3152105A1 (fr)	2019-11-29	2021-06-03	Wai Yip Thomas Lee	Composition comprenant de la rilpivirine et son utilisation pour le traitement de tumeurs ou du cancer

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5182111A (en) *	1987-11-17	1993-01-26	Boston University Research Foundation	In vivo delivery of active factors by co-cultured cell implants
US5047407A (en)	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en)	1988-06-27	1988-08-03	Wellcome Found	Therapeutic nucleosides
US5368864A (en) *	1988-11-25	1994-11-29	Henning Berlin Gmbh Chemie- Und Pharmawerk	Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en)	1989-12-22	1994-04-30	The Wellcome Foundation Ltd	Therapeutic nucleosides.
ES2093106T3 (es)	1990-07-19	1996-12-16	Otsuka Pharma Co Ltd	Preparacion solida.
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
WO1993009176A2 (fr) *	1991-10-29	1993-05-13	Clover Consolidated, Limited	Polysaccharides, polycations et lipides reticulables destines a l'encapsulation et la liberation de medicaments
ATE184787T1 (de)	1992-05-13	1999-10-15	Wellcome Found	Therapeutische kombinationen
JPH06316524A (ja)	1992-09-11	1994-11-15	Naoyuki Inoue	抗エイズウイルス剤
TW401303B (en) *	1994-07-01	2000-08-11	Janssen Pharmaceutica Nv	Anti-HIV triple combination
IT1281502B1 (it) *	1995-06-13	1998-02-18	Sardinian Antiviral Research C	Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
US6045829A (en) *	1997-02-13	2000-04-04	Elan Pharma International Limited	Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
DE60020382T2 (de)	1999-09-21	2006-01-26	Skyepharma Canada Inc., Verdun	Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
US6743446B2 (en) *	1999-12-15	2004-06-01	The Ohio State University Research Foundation	Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TW200800298A (en) *	2000-01-27	2008-01-01	Zentaris Ag	Compressed microparticles for dry injection
GEP20043285B (en)	2000-03-30	2004-07-26	Bristol Myers Squibb Co	Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections
US20040115268A1 (en) *	2000-04-26	2004-06-17	Control Delivery Systems, Inc.	Systemic delivery of antiviral agents
DE10050199A1 (de)	2000-10-11	2002-04-25	Ethicon Gmbh	Flächiges Implantat mit im Ultraschall detektierbaren Elementen
CA2431319A1 (fr)	2000-12-11	2002-06-20	Hiroto Bando	Composition medicinale dont la solubilite dans l'eau est amelioree
ES2333645T3 (es)	2001-06-22	2010-02-25	Bend Research, Inc.	Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros.
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
AU2002364701B8 (en)	2001-11-20	2006-06-22	Alkermes, Inc.	Compositions for sustained action product delivery
PL208533B1 (pl)	2002-08-09	2011-05-31	Janssen Pharmaceutica Nv	Sposób otrzymywania 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu oraz sposób otrzymywania związku pośredniego
WO2004022033A1 (fr) *	2002-09-04	2004-03-18	Microchips, Inc.	Technique et dispositif d'apport commande d'hormone parathyroide
JP2006508134A (ja)	2002-11-08	2006-03-09	グラクソ　グループ　リミテッド	医薬組成物
AU2003296760B2 (en)	2002-11-15	2009-11-19	Tibotec Pharmaceuticals Ltd.	Substituted indolepyridinium as anti-infective compounds
WO2004050068A1 (fr)	2002-11-29	2004-06-17	Janssen Pharmaceutica N.V.	Compositions pharmaceutiques comprenant un compose medicamenteux respectivement basique, tensioactif et base respectivement acide hydrosoluble et tolerable physiologiquement
CL2004000192A1 (es)	2003-02-07	2005-03-18	Janssen Pharmaceutica Nv	Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.
KR100629771B1 (ko) *	2004-01-27	2006-09-28	씨제이 주식회사	결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
RU2373923C2 (ru)	2004-06-08	2009-11-27	Вертекс Фармасьютикалз Инкорпорейтед	Фармацевтические композиции
MY191349A (en)	2004-08-27	2022-06-17	Bayer Pharmaceuticals Corp	New pharmaceutical compositions for the treatment of hyper-proliferative disorders
PT1632232E (pt)	2004-09-02	2011-08-02	Janssen Pharmaceutica Nv	Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
WO2006024668A1 (fr)	2004-09-02	2006-03-09	Janssen Pharmaceutica N.V.	Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7910577B2 (en)	2004-11-16	2011-03-22	Elan Pharma International Limited	Injectable nanoparticulate olanzapine formulations
TWI457136B (zh)	2005-04-04	2014-10-21	Tibotec Pharm Ltd	Ｈｉｖ-感染之預防
TW200710091A (en)	2005-04-11	2007-03-16	Tibotec Pharm Ltd	(1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
WO2006110889A2 (fr) *	2005-04-11	2006-10-19	The Board Of Trustees Of The Leland Stanford Junior University	Structure multicouche possedant une configuration predeterminee comprenant un agent
WO2006131806A2 (fr)	2005-06-07	2006-12-14	Pfizer Products Inc.	Formes multiparticulaires comprenant des medicaments a faible solubilite et supports qui entrainent une liberation rapide de medicament
CN101272769B (zh)	2005-07-28	2013-04-24	Isp投资有限公司	生物利用度提高的苯醌类化合物
RS52821B2 (sr)	2006-01-20	2021-07-30	Janssen Sciences Ireland Unlimited Co	Dugotrajno tretiranje hiv-infekcije sa tcm278
UA97641C2 (xx)	2006-06-23	2012-03-12	Тиботек Фармасьютикелз Лтд.	Водна суспензія 4-$$4-$$4-(2-ціаноетеніл)-2,6-диметилфеніл]аміно]-2-піримідиніл]аміно]бензонітрилу (tmc278)$водная суспензия 4-$$4-$$4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила (тмс278)
WO2008060360A2 (fr) *	2006-09-28	2008-05-22	Surmodics, Inc.	Dispositif médical implantable pourvu d'ouvertures pour administrer des agents bioactifs
TWI494133B (zh)	2007-03-14	2015-08-01	Tibotec Pharm Ltd	重組用粉末
CA2693044C (fr)	2007-07-12	2017-03-14	Tibotec Pharmaceuticals	Forme cristalline de of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
US20090123508A1 (en)	2007-10-04	2009-05-14	Boston Scientific Scimed, Inc.	Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
WO2010047819A1 (fr) *	2008-10-24	2010-04-29	Concert Pharmaceuticals, Inc.	Dérivés d'hydroxyéthylaminosulfonamide

2004
- 2004-09-02 MY MYPI20043578A patent/MY169670A/en unknown
- 2004-09-03 MX MXPA06002437A patent/MXPA06002437A/es active IP Right Grant
- 2004-09-03 JP JP2006525150A patent/JP5507791B2/ja not_active Expired - Lifetime
- 2004-09-03 NZ NZ545306A patent/NZ545306A/en not_active IP Right Cessation
- 2004-09-03 WO PCT/EP2004/052028 patent/WO2005021001A1/fr not_active Ceased
- 2004-09-03 PL PL04787096.9T patent/PL1663240T5/pl unknown
- 2004-09-03 US US10/570,228 patent/US20080200435A1/en not_active Abandoned
- 2004-09-03 CN CN2004800254267A patent/CN101060844B/zh not_active Expired - Lifetime
- 2004-09-03 EP EP04787096.9A patent/EP1663240B2/fr not_active Expired - Lifetime
- 2004-09-03 AU AU2004268390A patent/AU2004268390B2/en not_active Expired
- 2004-09-03 CA CA2537095A patent/CA2537095C/fr not_active Expired - Lifetime
- 2004-09-03 KR KR1020067003074A patent/KR20060090658A/ko not_active Ceased
- 2004-09-03 AP AP2006003551A patent/AP2109A/en active
2006
- 2006-01-30 IL IL173438A patent/IL173438A/en active Protection Beyond IP Right Term
- 2006-03-27 NO NO20061374A patent/NO334877B1/no active Protection Beyond IP Right Term
2009
- 2009-10-07 US US12/574,881 patent/US8841310B2/en not_active Expired - Lifetime
2011
- 2011-03-14 AU AU2011201123A patent/AU2011201123B2/en not_active Expired
- 2011-05-24 IL IL213104A patent/IL213104A/en active IP Right Grant
- 2011-10-12 JP JP2011224982A patent/JP2012051915A/ja not_active Withdrawn
2014
- 2014-06-26 AU AU2014203484A patent/AU2014203484B2/en active Active
- 2014-08-07 US US14/454,045 patent/US20140349971A1/en not_active Abandoned
- 2014-10-31 JP JP2014222770A patent/JP5820045B2/ja not_active Expired - Lifetime
- 2014-12-18 NO NO2014032C patent/NO2014032I1/no unknown
- 2014-12-18 NO NO2014031C patent/NO2014031I1/no not_active IP Right Cessation
- 2014-12-18 NO NO2014030C patent/NO2014030I1/no unknown
2015
- 2015-06-19 US US14/744,501 patent/US20150283135A1/en not_active Abandoned
- 2015-07-20 HR HRP20150798TT patent/HRP20150798T4/hr unknown
- 2015-10-20 NL NL300781C patent/NL300781I2/nl unknown
- 2015-10-20 LU LU92853C patent/LU92853I2/fr unknown
- 2015-10-21 FR FR15C0073C patent/FR15C0073I2/fr active Active
- 2015-10-21 LU LU92855C patent/LU92855I2/fr unknown
- 2015-10-21 NL NL300768C patent/NL300768I2/nl unknown
- 2015-10-21 FR FR15C0072C patent/FR15C0072I2/fr active Active
- 2015-10-21 CY CY2015038C patent/CY2015038I1/el unknown
- 2015-10-21 LU LU92854C patent/LU92854I2/fr unknown
- 2015-10-21 CY CY2015039C patent/CY2015039I1/el unknown
- 2015-10-21 HU HUS1500054C patent/HUS1500054I1/hu unknown
- 2015-10-21 BE BE2015C053C patent/BE2015C053I2/fr unknown
- 2015-10-21 CY CY2015040C patent/CY2015040I1/el unknown
- 2015-10-21 FR FR15C0071C patent/FR15C0071I2/fr active Active
- 2015-10-21 HU HUS1500052C patent/HUS1500052I1/hu unknown
- 2015-10-21 HU HUS1500053C patent/HUS1500053I1/hu unknown
2016
- 2016-08-05 AU AU2016210733A patent/AU2016210733B2/en active Active
- 2016-12-19 US US15/383,076 patent/US20170100398A1/en not_active Abandoned
- 2016-12-20 LT LTPA2016045C patent/LTPA2016045I1/lt unknown
- 2016-12-20 CY CY2016048C patent/CY2016048I2/el unknown
- 2016-12-20 LT LTPA2015035C patent/LTC1663240I2/lt unknown
- 2016-12-20 CY CY2016049C patent/CY2016049I2/el unknown
- 2016-12-20 FR FR16C1022C patent/FR16C1022I1/fr active Active
- 2016-12-20 FR FR16C1024C patent/FR16C1024I1/fr active Active
- 2016-12-20 FI FIEP04787096.9T patent/FI1663240T4/fi active
- 2016-12-20 HU HUS1600058C patent/HUS1600058I1/hu unknown
- 2016-12-20 NO NO2016025C patent/NO2016025I1/no unknown
- 2016-12-20 NO NO2016026C patent/NO2016026I1/no unknown
- 2016-12-20 HU HUS1600059C patent/HUS1600059I1/hu unknown
2018
- 2018-04-11 US US15/950,548 patent/US20180228800A1/en not_active Abandoned
2019
- 2019-02-06 AU AU2019200813A patent/AU2019200813A1/en not_active Abandoned
- 2019-03-21 US US16/360,693 patent/US20190216807A1/en not_active Abandoned
2020
- 2020-02-07 US US16/784,404 patent/US20200171027A1/en not_active Abandoned
2021
- 2021-09-13 US US17/472,870 patent/US20220008417A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN101060844B (zh)	2012-01-04
FR15C0072I2 (fr)	2019-05-17
AU2011201123B2 (en)	2013-10-10
HUS1500054I1 (hu)	2016-03-29
FI1663240T4 (fi)	2023-04-25
US20140349971A1 (en)	2014-11-27
EP1663240B1 (fr)	2015-04-22
NO2014031I1 (no)	2015-01-05
NL300768I1 (fr)	2015-12-16
AP2109A (en)	2010-02-26
JP2007520443A (ja)	2007-07-26
US20200171027A1 (en)	2020-06-04
JP2012051915A (ja)	2012-03-15
FR15C0073I1 (fr)	2015-04-12
NO20061374L (no)	2006-03-27
HUS1600059I1 (hu)	2017-02-28
NO2014031I2 (no)	2014-12-18
AU2016210733B2 (en)	2018-11-08
US20220008417A1 (en)	2022-01-13
JP5820045B2 (ja)	2015-11-24
NO2014030I1 (no)	2015-01-05
AP2006003551A0 (en)	2006-04-30
NO2014032I2 (no)	2014-12-18
CY2015040I2 (el)	2016-08-31
NZ545306A (en)	2009-11-27
FR16C1024I1 (fr)	2017-02-03
NL300768I2 (nl)	2023-08-09
US20180228800A1 (en)	2018-08-16
HRP20150798T1 (hr)	2015-09-11
CY2015039I2 (el)	2016-08-31
US8841310B2 (en)	2014-09-23
CY2015039I1 (el)	2016-08-31
AU2019200813A1 (en)	2019-02-28
EP1663240B2 (fr)	2023-03-01
NO2016025I1 (fr)	2016-12-20
AU2014203484A1 (en)	2014-07-17
CA2537095C (fr)	2012-05-29
AU2004268390A1 (en)	2005-03-10
MXPA06002437A (es)	2006-06-20
FR16C1022I1 (fr)	2017-02-03
FR15C0071I2 (fr)	2016-02-12
NL300781I1 (fr)	2016-04-19
CY2015038I2 (el)	2016-08-31
LTC1663240I2 (lt)	2022-05-25
NO2014030I2 (no)	2014-12-18
IL213104A0 (en)	2011-07-31
WO2005021001A1 (fr)	2005-03-10
US20150283135A1 (en)	2015-10-08
CY2016049I1 (el)	2017-07-12
AU2011201123A1 (en)	2011-04-07
CA2537095A1 (fr)	2005-03-10
AU2014203484B2 (en)	2016-09-29
EP1663240A1 (fr)	2006-06-07
CY2015038I1 (el)	2016-08-31
FR15C0071I1 (fr)	2015-04-12
CY2016048I1 (el)	2017-07-12
NO2014032I1 (no)	2015-01-05
US20170100398A1 (en)	2017-04-13
CY2015040I1 (el)	2016-08-31
US20190216807A1 (en)	2019-07-18
MY169670A (en)	2019-05-08
PL1663240T5 (pl)	2024-02-26
LU92853I2 (fr)	2015-12-21
FR15C0072I1 (fr)	2015-04-12
NO334877B1 (no)	2014-06-23
LTPA2016045I1 (lt)	2017-01-10
LTPA2016044I1 (lt)	2017-01-10
CY2016049I2 (el)	2017-07-12
HRP20150798T4 (hr)	2023-06-09
JP5507791B2 (ja)	2014-05-28
HUS1600058I1 (hu)	2017-02-28
JP2015044839A (ja)	2015-03-12
CN101060844A (zh)	2007-10-24
IL213104A (en)	2016-02-29
CY2016048I2 (el)	2017-07-12
BE2015C053I2 (fr)	2023-12-14
KR20060090658A (ko)	2006-08-14
NO2016026I1 (no)	2016-12-20
FR15C0073I2 (fr)	2016-02-12
AU2016210733A1 (en)	2016-08-25
HUS1500052I1 (hu)	2016-03-29
IL173438A (en)	2012-03-29
HK1092698A1 (en)	2007-02-16
US20100029591A1 (en)	2010-02-04
LU92855I2 (fr)	2015-12-21
NL300781I2 (fr)	2016-04-19
US20080200435A1 (en)	2008-08-21
HUS1500053I1 (hu)	2016-03-29
AU2004268390B2 (en)	2011-03-31
IL173438A0 (en)	2006-06-11
PL1663240T3 (pl)	2015-10-30

Publication	Publication Date	Title
LU92854I2 (fr)	2015-12-21	Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil
BG108269A (en)	2004-12-30	Pyrazolopyrimidines as therapeutic agents
BR0308243A (pt)	2005-01-11	Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
WO2002042462A3 (fr)	2003-06-19	Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique
BR0308452A (pt)	2006-06-06	composições farmacêuticas e métodos de preparação de composição farmacêutica
LU92496I2 (fr)	2014-09-10	Combinaison de dapagliflozine ou d'un sel pharmaceutiquement acceptable de celle-ci et de merformineou d'un sel pharmaceutiquement acceptable de cell-ci, telle que protégée par le brevet de base EP1506211 B1
GB0223040D0 (en)	2002-11-13	Therapeutic compounds
BG108268A (en)	2005-04-30	Pyrazolopyrimidines as therapeutic agents
DK1296671T3 (da)	2008-06-16	Gabapentinanaloger til sövnforstyrrelser
EP1827468A4 (fr)	2009-08-05	Acetate de leuprolide et inhibiteurs de l'acetylcholinesterase ou antagonistes des recepteurs nmda pour le traitement de la maladie d'alzheimer
TNSN04165A1 (en)	2007-03-12	Substituted hydroxyethylamines
BR0209020A (pt)	2004-08-10	Composição farmacêutica de polialilamina
MXPA04000278A (es)	2004-05-04	Uso de antagonistas del receptor nk-1 con estructura piridinica para tratamiento de lesiones cerebrales, espinales o neuronales.
IS2517B (is)	2009-06-15	Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
TNSN04071A1 (fr)	2006-06-01	Derives de 3-azabicyclo [3.1.0] hexane servant d'antagonistes des recepteurs d'opioides
UA90518C2 (ru)	2010-05-11	Фармацевтическая композиция в форме таблетки, которая имеет улучшеное всасывание при трансбукальном введение, которая содержит наркотический активный ингредиент и амин
EA200800880A1 (ru)	2009-02-27	Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
SE0102440D0 (sv)	2001-07-05	New compound
SG153661A1 (en)	2009-07-29	Formulation and methods for the treatment of thrombocythemia
SG160197A1 (en)	2010-04-29	Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
DE60137451D1 (de)	2009-03-05	N-substituierte Amide als NK1 Rezeptor Antagonisten
IL172213A0 (en)	2009-02-11	Compounds useful in the therapy of alzheimer's disease and formulations containing them
MXPA01009032A (es)	2004-11-10	Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso se la produccion de il-12.
NO20033634L (no)	2003-10-08	GLyT-1-inhibitorer
BR0213463A (pt)	2004-11-09	Composições farmacêuticas contendo macrólidos